載入...
P08.65 Evaluation of Clinical Benefit in patients treated with Bevacizumab
OBJECTIVE: Bevacizumab (BV), a monoclonal antibody for the treatment of recurrence of glioblastoma, was approved in 2009 in USA whereas today no such approval there is in the European Union. BV showed a higher response rates and prolongation of median at 6 month progression free survival (PFS) compa...
Na minha lista:
| 發表在: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5782693/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.198 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|